Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy
- 277 Downloads
Male breast cancer (MBC) is rare and poorly understood. Like female breast cancer (FBC), MBCs are highly sensitive to hormonal changes, and hyperestrogenism, specifically, represents a major risk factor for MBC. MBC is considered similar to late-onset, post-menopausal estrogen/progesteron receptors positive FBC (ER+/PR+). Sulfotransferase 1A1 (SULT1A1) is an enzyme involved in the metabolism of estrogens. Recently, SULT1A1 common functional polymorphism Arg213His (638G>A) variant has been found to be associated with increased breast cancer (BC) risk, particularly in post-menopausal women. For this reason, we decided to explore whether SULT1A1 Arg213His could exert an effect on MBC development. The primary aim of this study was to evaluate the influence of the SULT1A1 Arg213His polymorphism on MBC risk. The secondary aim was to investigate possible associations with relevant clinical–pathologic features of MBC. A total of 394 MBC cases and 786 healthy male controls were genotyped for SULT1A1 Arg213His polymorphism by PCR–RFLP and high-resolution melting analysis. All MBC cases were characterized for relevant clinical–pathologic features. A significant difference in the distribution of SULT1A1 Arg213His genotypes was found between MBC cases and controls (P < 0.0001). The analysis of genotype-specific risk showed a significant increased MBC risk in individuals with G/A (OR 1.97, 95 % CI 1.50–2.59; P < 0.0001) and A/A (OR 3.09, 95 % CI 1.83–5.23; P < 0.0001) genotypes in comparison to wild-type genotype, under co-dominant model. A significant association between SULT1A1 risk genotypes and HER2 status emerged. Results indicate that SULT1A1 Arg213His may act as a low-penetrance risk allele for developing MBC and could be associated with a specific tumor subtype associated with HER2 overexpression.
KeywordsMale breast cancer Estrogens Estrogen receptor Sulfotransferase 1A1 (SULT1A1) SULT1A1 Arg213His polymorphism
The authors wish to thank Lesley Pritikin for her assistance with preparation of the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
This work was supported by AIRC (Associazione Italiana Ricerca Cancro, Grant No. IG12780) to L.O., FIRC (Fondazione Italiana Ricerca Cancro triennial fellowship “Mario e Valeria Rindi”) to V.S., and ITT (Istituto Tumori Toscano, triennial Grant 2010, Grant No. 6204) to D.P.
- 2.Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28:2114–2122PubMedCentralPubMedCrossRefGoogle Scholar
- 3.Brinton LA, Cook MB, McCormack V, Johnson KC, Olsson H, Casagrande JT, Cooke R, Falk RT, Gapstur SM, Gaudet MM, Gaziano JM, Gkiokas G, Guénel P, Henderson BE, Hollenbeck A, Hsing AW, Kolonel LN, Isaacs C, Lubin JH, Michels KB, Negri E, Parisi D, Petridou ET, Pike MC, Riboli E, Sesso HD, Snyder K, Swerdlow AJ, European Rare Cancer Study Group, Trichopoulos D, Ursin G, van Den Brandt PA, Van Den Eeden SK, Weiderpass E, Willett WC, Ewertz M, Thomas DB (2014) Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst 106(3):djt465. doi: 10.1093/jnci/djt465 PubMedCrossRefGoogle Scholar
- 8.Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR (2001) Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomark Prev 10:89–94Google Scholar
- 9.Tang D, Rundle A, Mooney L, Cho S, Schnabel F, Estabrook A, Kelly A, Levine R, Hibshoosh H, Perera F (2003) Sulfotransferase 1A1 (SULT1A1) polymorphisms PAH-DNA adduct levels in breast tissue and breast cancer risk in a case–control study. Breast Cancer Res Treat 78(2):217–222PubMedCrossRefGoogle Scholar
- 19.Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D (2012) Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicentre study in Italy. Breast Cancer Res Treat 134(1):411–418PubMedCrossRefGoogle Scholar
- 20.Ottini L, Silvestri V, Saieva C, Rizzolo P, Zanna I, Falchetti M, Masala G, Navazio AS, Graziano V, Bianchi S, Manoukian S, Barile M, Peterlongo P, D’Amico C, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D (2013) Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. Breast Cancer Res Treat 138(3):861–868PubMedCrossRefGoogle Scholar
- 21.Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hollsten J, Pollock BH, Kuhn JG (2006) Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Res Treat 95(1):13–16PubMedCrossRefGoogle Scholar
- 26.Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L (2013) SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures? J Cell Mol Med 17(5):605–607PubMedCrossRefGoogle Scholar